| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 1NKEMIA Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 290,35 | +0,05 % | Opening Bell: Robinhood, Alphabet, Amgen, Axon Enterprise, SolarEdge, Marvell Technology, Snap | Nach mehreren schwachen Handelstagen konnten sich die US-Börsen am Donnerstag wieder deutlich erholen. Ausschlaggebend waren robuste Daten vom Arbeitsmarkt, die diesmal für Erleichterung statt für Zinssorgen... ► Artikel lesen | |
| 4SC | 0,642 | -4,18 % | 4SC AG ringt um Zukunft nach schwerem Rückschlag | Das Biotech-Unternehmen 4SC AG (ISIN: DE000A3E5C40) aus Planegg-Martinsried steht an einem kritischen Wendepunkt. Nachdem die Europäische Arzneimittelbehörde EMA im Mai die Zulassung für das Krebsmedikament... ► Artikel lesen | |
| AAP IMPLANTATE | 1,390 | -4,14 % | EQS-NVR: aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: aap Implantate AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach §... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,910 | 0,00 % | COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update | COSCIENS voluntarily delists from Nasdaq, while retaining the Company's listing on the TSX COSCIENS restructuring results in significantly lower cash outflow with operating expenses down 59% vs. Q3... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| ALDEYRA | 4,550 | -0,61 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| AGIOS | 37,600 | -0,53 % | Agios Pharmaceuticals, Inc.: Agios Reports Third Quarter 2025 Financial Results and Provides Business Update | $12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia... ► Artikel lesen | |
| AGENUS | 3,820 | +4,95 % | Agenus Inc.: Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances | France grants reimbursed access with patients having commenced treatment Two-year BOT/BAL survival presented at ESMO spanning more than five cancers in over 400 patients Phase 3 on... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,030 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 21.10.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 21.10.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 21.10.2025.ISIN NameCA80013R2063 SANDSTORM... ► Artikel lesen | |
| BIOLASE | 0,075 | 0,00 % | BIOLASE MG LLC: BIOLASE Emerges Stronger Than Ever Under New Ownership by MegaGen Implant | FOOTHILL RANCH, Calif., Sept. 10, 2025 /PRNewswire/ -- BIOLASE, the global leader in dental laser technology, proudly announces a new chapter in its history... ► Artikel lesen | |
| ACTINIUM | 1,149 | +1,23 % | Actinium Pharmaceuticals, Inc. - 10-Q, Quarterly Report | ||
| AKEBIA | 1,600 | +0,50 % | Akebia Therapeutics, Inc.: Vafseo (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat ... | CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| ALKERMES | 27,000 | -0,74 % | Alkermes plc: Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 | - Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 -
-... ► Artikel lesen | |
| ABEONA THERAPEUTICS | 4,400 | +2,80 % | Abeona Therapeutics Inc.: Abeona Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates | - First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with... ► Artikel lesen | |
| 3SBIO | 3,360 | -1,18 % | Pfizer Completes Licensing Agreement With 3SBio For Cancer Drug | NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Thursday said it has completed the licensing agreement with 3SBio, Inc. for exclusive rights to develop and sell 3SBio's SSGJ-707.As per the deal... ► Artikel lesen |